

Benjamin M Ellingson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3719327/publications.pdf>

Version: 2024-02-01

215
papers

9,670
citations

38742

50
h-index

48315

88
g-index

215
all docs

215
docs citations

215
times ranked

11055
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
2	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	10.7	582
3	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	1.6	420
4	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	1.2	346
5	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 307-320.	4.4	294
6	Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 538-548.	3.4	240
7	Ivosenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	1.6	167
8	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. <i>Journal of Neuro-Oncology</i> , 2017, 134, 495-504.	2.9	160
9	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. <i>Radiology</i> , 2014, 271, 200-210.	7.3	150
10	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 491-498.	2.9	149
11	Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. <i>Pain</i> , 2013, 154, 1528-1541.	4.2	134
12	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	1.2	131
13	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. <i>NeuroImage</i> , 2012, 59, 908-916.	4.2	128
14	¹⁸ F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2012, 53, 29-36.	5.0	122
15	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	2.9	118
16	Treatment Response Evaluation Using ¹⁸ F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3550-3559.	7.0	115
17	Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 506.	4.2	114
18	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112

#	ARTICLE	IF	CITATIONS
19	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275.	1.2	109
20	¹⁸ F-FDOPA and ¹⁸ F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012, 14, 1079-1089.	1.2	99
21	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using ¹⁸ F-FMISO PET and MRI. <i>Clinical Cancer Research</i> , 2016, 22, 5079-5086.	7.0	99
22	Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 336-344.	4.2	98
23	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013, 15, 370-381.	1.2	97
24	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	1.2	96
25	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 401-409.	1.2	95
26	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. <i>Journal of Neuro-Oncology</i> , 2014, 116, 373-379.	2.9	95
27	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. <i>Neuro-Oncology</i> , 2013, 15, 626-634.	1.2	91
28	Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. <i>Neurobiology of Disease</i> , 2019, 123, 115-121.	4.4	91
29	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014, 16, 414-420.	1.2	82
30	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10220-10225.	7.1	79
31	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 228-234.	1.3	77
32	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 333-343.	1.2	74
33	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). <i>Neuro-Oncology</i> , 2015, 17, v158.4-v159.	1.2	70
34	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 1151-1161.	1.2	69
35	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC) MRI estimates of cerebral blood volume (CBV) in human gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1472-1477.	3.4	68
36	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017, 19, 89-98.	1.2	68

#	ARTICLE	IF	CITATIONS
37	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
38	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012, 106, 111-119.	2.9	67
39	Diffusion tensor imaging predicts functional impairment in mild-to-moderate cervical spondylotic myelopathy. <i>Spine Journal</i> , 2014, 14, 2589-2597.	1.3	67
40	Patterns of brain structural connectivity differentiate normal weight from overweight subjects. <i>NeuroImage: Clinical</i> , 2015, 7, 506-517.	2.7	67
41	Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 102, 95-103.	2.9	65
42	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	1.2	65
43	Unique Microstructural Changes in the Brain Associated with Urological Chronic Pelvic Pain Syndrome (UCPPS) Revealed by Diffusion Tensor MRI, Super-Resolution Track Density Imaging, and Statistical Parameter Mapping: A MAPP Network Neuroimaging Study. <i>PLoS ONE</i> , 2015, 10, e0140250.	2.5	64
44	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
45	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	7.0	62
46	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
47	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. <i>International Journal of Oncology</i> , 2015, 46, 1883-1892.	3.3	57
48	Pros and cons of current brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii2-vii11.	1.2	56
49	Brain White Matter Abnormalities in Female Interstitial Cystitis/Bladder Pain Syndrome: A MAPP Network Neuroimaging Study. <i>Journal of Urology</i> , 2015, 194, 118-126.	0.4	54
50	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 1820-1828.	7.0	54
51	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	7.0	53
52	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	2.8	51
53	Advances in MR imaging for cervical spondylotic myelopathy. <i>European Spine Journal</i> , 2015, 24, 197-208.	2.2	47
54	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naïve human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	4.1	47

#	ARTICLE	IF	CITATIONS
55	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <i>Neuro-Oncology</i> , 2020, 22, 705-717.	1.2	47
56	Prediction of Neurological Impairment in Cervical Spondylotic Myelopathy using a Combination of Diffusion MRI and Proton MR Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139451.	2.5	46
57	Ex vivo diffusion tensor imaging and quantitative tractography of the rat spinal cord during long-term recovery from moderate spinal contusion. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 1068-1079.	3.4	45
58	Regional and Voxel-Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) and Arterial Spin Labeling (ASL) in Brain Tumors. <i>Journal of Neuroimaging</i> , 2014, 24, 23-30.	2.0	45
59	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. <i>Neuro-Oncology</i> , 2018, 20, 457-471.	1.2	44
60	Dynamic Susceptibility Contrast MR Imaging in Glioma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 649-670.	1.1	43
61	Brain white matter changes associated with urological chronic pelvic pain syndrome: multisite neuroimaging from a MAPP case-control study. <i>Pain</i> , 2016, 157, 2782-2791.	4.2	43
62	Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1131-1143.	3.0	42
63	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. <i>European Journal of Radiology</i> , 2017, 97, 31-36.	2.6	42
64	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	1.2	41
65	Emerging techniques and technologies in brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii12-vii23.	1.2	41
66	Nitroxoline induces apoptosis and slows glioma growth in vivo. <i>Neuro-Oncology</i> , 2015, 17, 53-62.	1.2	41
67	Lesion growth and degeneration patterns measured using diffusion tensor 9.4-T magnetic resonance imaging in rat spinal cord injury. <i>Journal of Neurosurgery: Spine</i> , 2010, 13, 181-192.	1.7	40
68	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. <i>American Journal of Neuroradiology</i> , 2016, 37, 1440-1446.	2.4	39
69	Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas. <i>American Journal of Neuroradiology</i> , 2017, 38, 478-484.	2.4	39
70	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013, 15, 382-390.	1.2	38
71	Simultaneous p^H-sensitive and oxygen-sensitive ^{MRI} of human gliomas at 3 ^T using multi-echo amine proton chemical exchange saturation transfer spin- and gradient echo echo-planar imaging (^{CEST}SAGE&EPI</sup>). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	3.0	38
72	Imaging Techniques in Spinal Cord Injury. <i>World Neurosurgery</i> , 2014, 82, 1351-1358.	1.3	37

#	ARTICLE	IF	CITATIONS
73	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 122, 497-505.	2.9	37
74	Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. <i>Magnetic Resonance in Medicine</i> , 2012, 67, 237-245.	3.0	36
75	Morphology and Morphometry of Human Chronic Spinal Cord Injury Using Diffusion Tensor Imaging and Fuzzy Logic. <i>Annals of Biomedical Engineering</i> , 2008, 36, 224-236.	2.5	35
76	Diffusion Tensor Magnetic Resonance Tractography of the Prostate: Feasibility for Mapping Periprostatic Fibers. <i>Urology</i> , 2012, 80, 219-223.	1.0	34
77	Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. <i>Microbiome</i> , 2021, 9, 236.	11.1	34
78	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2011, 105, 91-101.	2.9	33
79	3D visualization of subdural electrode shift as measured at craniotomy reopening. <i>Epilepsy Research</i> , 2011, 94, 102-109.	1.6	33
80	DTI of tuber and perituberal tissue can predict epileptogenicity in tuberous sclerosis complex. <i>Neurology</i> , 2015, 85, 2011-2015.	1.1	33
81	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014, 16, vii24-vii35.	1.2	32
82	¹⁸ F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 399-409.	2.9	32
83	Spinal Cord Perfusion MR Imaging Implicates Both Ischemia and Hypoxia in the Pathogenesis of Cervical Spondylosis. <i>World Neurosurgery</i> , 2019, 128, e773-e781.	1.3	32
84	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	3.3	32
85	Functional correlates of diffusion tensor imaging in spinal cord injury. <i>Biomedical Sciences Instrumentation</i> , 2008, 44, 28-33.	0.2	30
86	Multisite, multimodal neuroimaging of chronic urological pelvic pain: Methodology of the MAPP Research Network. <i>NeuroImage: Clinical</i> , 2016, 12, 65-77.	2.7	29
87	Relationship Between [¹⁸ F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	2.6	28
88	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.2	28
89	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	2.9	28
90	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. <i>Neuro-Oncology</i> , 2022, 24, 770-778.	1.2	28

#	ARTICLE	IF	CITATIONS
91	In vivo diffusion tensor imaging of the rat spinal cord at 9.4T. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 634-642.	3.4	27
92	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 868-879.	1.8	27
93	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015, 21, 4373-4383.	7.0	27
94	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC) MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	3.4	27
95	Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2020, 22, 1658-1666.	1.2	27
96	Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders. <i>NeuroImage</i> , 2016, 124, 1232-1237.	4.2	26
97	Alterations in Cortical Thickness and Subcortical Volume are Associated With Neurological Symptoms and Neck Pain in Patients With Cervical Spondylosis. <i>Neurosurgery</i> , 2019, 84, 588-598.	1.1	26
98	Correlation between degree of subvoxel spinal cord compression measured with super-resolution tract density imaging and neurological impairment in cervical spondylotic myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2015, 22, 631-638.	1.7	25
99	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	2.9	25
100	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	1.2	24
101	Radiologic progression of glioblastoma under therapy – an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018, 20, 557-566.	1.2	24
102	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	2.4	24
103	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	7.0	24
104	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015, 9, 617-624.	2.7	23
105	Resting-State Functional Magnetic Resonance Imaging Connectivity of the Brain Is Associated with Altered Sensorimotor Function in Patients with Cervical Spondylosis. <i>World Neurosurgery</i> , 2018, 119, e740-e749.	1.3	23
106	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	1.2	23
107	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	3.3	23
108	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	1.2	23

#	ARTICLE	IF	CITATIONS
109	Gray and White Matter Delineation in the Human Spinal Cord Using Diffusion Tensor Imaging and Fuzzy Logic. <i>Academic Radiology</i> , 2007, 14, 847-858.	2.5	22
110	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. <i>Scientific Reports</i> , 2018, 8, 14429.	3.3	22
111	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Cancer Imaging</i> , 2014, 14, 31.	2.8	21
112	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. <i>PLoS ONE</i> , 2018, 13, e0198548.	2.5	21
113	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 127-136.	1.2	20
114	Advanced Imaging in the Evaluation of Migraine Headaches. <i>Neuroimaging Clinics of North America</i> , 2019, 29, 301-324.	1.0	20
115	pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI). <i>NeuroImage: Clinical</i> , 2019, 22, 101736.	2.7	19
116	Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 454-462.	1.5	18
117	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 258-265.	0.6	18
118	Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2010, 97, 419-423.	2.9	17
119	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 33-47.	3.0	17
120	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	1.2	17
121	High-resolution in vivo diffusion tensor imaging of the injured cat spinal cord using self-navigated, interleaved, variable-density spiral acquisition (SNAILS-DTI). <i>Magnetic Resonance Imaging</i> , 2010, 28, 1353-1360.	1.8	16
122	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015, 4, 247-256.	3.0	16
123	Reproducibility, temporal stability, and functional correlation of diffusion MR measurements within the spinal cord in patients with asymptomatic cervical stenosis or cervical myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2018, 28, 472-480.	1.7	16
124	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. <i>Cancer Science</i> , 2016, 107, 1110-1116.	3.9	16
125	Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. <i>Tomography</i> , 2018, 4, 123-137.	1.8	16
126	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. , 2006, 2006, 1885-8.		15

#	ARTICLE	IF	CITATIONS
127	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535.	1.2	15
128	Disease-Related Microstructural Differences in the Brain in Women With Provoked Vestibulodynia. <i>Journal of Pain</i> , 2018, 19, 528.e1-528.e15.	1.4	15
129	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. <i>American Journal of Neuroradiology</i> , 2018, 39, 43-45.	2.4	15
130	Compensatory brainstem functional and structural connectivity in patients with degenerative cervical myelopathy by probabilistic tractography and functional MRI. <i>Brain Research</i> , 2020, 1749, 147129.	2.2	14
131	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	1.1	14
132	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 257-266.	2.9	13
133	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	3.3	13
134	Voxelwise and Patientwise Correlation of ¹⁸ F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	5.0	13
135	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	2.8	13
136	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 551-558.	2.9	12
137	Understanding brain penetrance of anticancer drugs. <i>Neuro-Oncology</i> , 2018, 20, 589-596.	1.2	12
138	Rate of change in maximum ¹⁸ F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 147, 135-145.	2.9	12
139	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015, 1, 37-43.	1.8	12
140	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	1.2	12
141	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. <i>Neuro-Oncology</i> , 2021, 23, 189-198.	1.2	11
142	High Order Diffusion Tensor Imaging in Human Glioblastoma. <i>Academic Radiology</i> , 2011, 18, 947-954.	2.5	10
143	Topographical Distribution of Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2016, 31, 636-645.	1.4	10
144	Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 222, 397-410.	2.0	10

#	ARTICLE	IF	CITATIONS
145	Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. <i>Scientific Reports</i> , 2021, 11, 15011.	3.3	10
146	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance) <i>Tj ETQq0 0 0 rgBT1/0 Overlock 10 Tf 50 6</i>	1.0	6
147	Diffusion tensor magnetic resonance imaging in spinal cord injury. <i>Concepts in Magnetic Resonance Part A: Bridging Education and Research</i> , 2008, 32A, 219-237.	0.5	9
148	Neck disability in patients with cervical spondylosis is associated with altered brain functional connectivity. <i>Journal of Clinical Neuroscience</i> , 2019, 69, 149-154.	1.5	9
149	Sodium MR Neuroimaging. <i>American Journal of Neuroradiology</i> , 2021, 42, 1920-1926.	2.4	9
150	A new technique for imaging the human spinal cord in vivo. <i>Biomedical Sciences Instrumentation</i> , 2006, 42, 255-60.	0.2	9
151	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	1.2	9
152	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. <i>PET Clinics</i> , 2013, 8, 201-217.	3.0	8
153	Evaluation of Encephaloduroarteriosynangiosis Efficacy Using Probabilistic Independent Component Analysis Applied to Dynamic Susceptibility Contrast Perfusion MRI. <i>American Journal of Neuroradiology</i> , 2017, 38, 507-514.	2.4	8
154	Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study. <i>PLoS ONE</i> , 2018, 13, e0206807.	2.5	8
155	â€œAerobic glycolytic imagingâ€ of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	2.7	8
156	Incidence, molecular characteristics, and imaging features of â€œclinically-defined pseudoprogressionâ€ in newly diagnosed glioblastoma treated with chemoradiation. <i>Journal of Neuro-Oncology</i> , 2022, 159, 509-518.	2.9	8
157	Structural changes in functional gastrointestinal disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 200-202.	17.8	7
158	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. <i>CNS Oncology</i> , 2019, 8, CNS35.	3.0	7
159	Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors. <i>Cancer Imaging</i> , 2019, 19, 14.	2.8	7
160	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3135-3144.	7.0	7
161	Influence of phosphate concentration on amine, amide, and hydroxyl CEST contrast. <i>Magnetic Resonance in Medicine</i> , 2021, 85, 1062-1078.	3.0	7
162	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	2.2	7

#	ARTICLE	IF	CITATIONS
163	Detection of cerebral reorganization associated with degenerative cervical myelopathy using diffusion spectral imaging (DSI). <i>Journal of Clinical Neuroscience</i> , 2021, 86, 164-173.	1.5	7
164	Amine-Weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. <i>NMR in Biomedicine</i> , 2023, 36, .	2.8	7
165	Characteristics of Mid- to Long-Latency Spinal Somatosensory Evoked Potentials following Spinal Trauma in the Rat. <i>Journal of Neurotrauma</i> , 2008, 25, 1323-1334.	3.4	6
166	Diffusion-Weighted Imaging of the Spinal Cord. , 2014, , 123-145.		6
167	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 116, 601-608.	2.9	6
168	Focal cortical dysplasia imaging discrepancies between MRI and FDG-PET: Unique association with temporal lobe location. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 81, 180-185.	2.0	6
169	Pathophysiology, classification, and MRI parallels in microvascular disease of the heart and brain. <i>Microcirculation</i> , 2020, 27, e12648.	1.8	6
170	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. <i>Schizophrenia Research</i> , 2021, 231, 179-188.	2.0	6
171	A novel bicompartmental mathematical model of glioblastoma multiforme. <i>International Journal of Oncology</i> , 2015, 46, 825-832.	3.3	5
172	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. <i>Oncology Reports</i> , 2015, 33, 2883-2888.	2.6	5
173	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	2.9	5
174	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020, 147, 643-652.	2.9	5
175	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	2.2	5
176	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2022, 16, 239-251.	2.1	5
177	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	3.3	5
178	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. <i>PET Clinics</i> , 2013, 8, 163-182.	3.0	4
179	Standardized Brain Tumor Imaging Protocol for Clinical Trials. <i>American Journal of Neuroradiology</i> , 2015, 36, E65-E66.	2.4	4
180	Assessing variability in brain tumor segmentation to improve volumetric accuracy and characterization of change. , 2016, 2016, 380-383.		4

#	ARTICLE	IF	CITATIONS
181	Selective middle cerebral artery occlusion in the rabbit: Technique and characterization with pathologic findings and multimodal MRI. <i>Journal of Neuroscience Methods</i> , 2019, 313, 6-12.	2.5	4
182	Novel tonometer device distinguishes brain stiffness in epilepsy surgery. <i>Scientific Reports</i> , 2020, 10, 20978.	3.3	4
183	Supraspinal functional and structural plasticity in patients undergoing surgery for degenerative cervical myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2021, , 1-9.	1.7	4
184	Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2020, 45, e505-e511.	1.3	4
185	On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1346-1347.	1.2	3
186	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. <i>Neuro-Oncology Practice</i> , 2019, 6, 103-111.	1.6	3
187	Minimizing echo and repetition times in magnetic resonance imaging using a double half-space acquisition and low-rank reconstruction. <i>NMR in Biomedicine</i> , 2021, 34, e4458.	2.8	3
188	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. <i>Data in Brief</i> , 2021, 35, 106950.	1.0	3
189	Sex-Dependent Cortical Volume Changes in Patients with Degenerative Cervical Myelopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3965.	2.4	3
190	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2007-2007.	1.6	3
191	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2078-TPS2078.	1.6	3
192	Novel Magnetic Resonance Imaging Techniques in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 137-146.	1.2	2
193	A physical phantom for amine chemical exchange saturation transfer (CEST) MRI. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 569-580.	2.0	2
194	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab082.	0.7	2
195	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	2.9	2
196	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 395-403.	2.0	2
197	Somatosensory Functional Correlates of Spinal Cord Diffusion Tensor Imaging during Long-term Recovery from Spinal Contusion. <i>Neurosurgery</i> , 2008, 62, 1411-1412.	1.1	2
198	Recovery of Supraspinal Microstructural Integrity and Connectivity in Patients Undergoing Surgery for Degenerative Cervical Myelopathy. <i>Neurosurgery</i> , 2022, 90, 447-456.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Optimal diffusion tensor indices for imaging the human spinal cord. Biomedical Sciences Instrumentation, 2007, 43, 128-33.	0.2	2
200	Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. CNS Oncology, 2022, 11, CNS84.	3.0	2
201	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. Cancers, 2022, 14, 2520.	3.7	2
202	Editorial: Novel spinal cord imaging. Journal of Neurosurgery: Spine, 2011, 15, 645-647.	1.7	1
203	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
204	A study of 3D radial density adapted trajectories for sodium imaging. Magnetic Resonance Imaging, 2021, 83, 89-95.	1.8	1
205	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	2.8	1
206	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. Neurotherapeutics, 2022, 19, 1855-1868.	4.4	1
207	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. Neuro-Oncology, 2014, 16, v25-v25.	1.2	0
208	SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T. Schizophrenia Bulletin, 2017, 43, S189-S189.	4.3	0
209	The Path Forward: The Standardized Brain Tumor Imaging Protocol (BTIP) for Multicenter Trials. , 2020, , 267-282.		0
210	Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas. , 2020, , 49-60.		0
211	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
212	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. Tomography, 2022, 8, 1437-1452.	1.8	0
213	Characterizing malignant transformation in patients with IDH-mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2065-2065.	1.6	0
214	Evaluation of the response assessment criteria in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2020-2020.	1.6	0
215	A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2043-2043.	1.6	0